<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5159">
  <stage>Registered</stage>
  <submitdate>10/05/2011</submitdate>
  <approvaldate>10/05/2011</approvaldate>
  <nctid>NCT01352442</nctid>
  <trial_identification>
    <studytitle>Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes</studytitle>
    <scientifictitle>A Prospective Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT Implanted Intrastromally for Modified Monovision in Presbyopic Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACU-P10-020B</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Presbyopia</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - AcuFocus Corneal Inlay ACI 7000PDT

Experimental: AcuFocus Corneal Inlay - The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.


Treatment: devices: AcuFocus Corneal Inlay ACI 7000PDT
corneal inlay

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Uncorrected Near Visual Acuity 20/32 or Better</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Subjective Rating of Near Visual Acuity at 12 Months as Measured by Subjective Questionnaire - Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subjects must sign and be given a copy of the written Informed Consent form.

          2. Subjects must be emmetropes needing a magnitude of +1.00D to +2.50D of reading add.

          3. Subjects must have distance corrected near visual acuity worse than 20/40 and better
             than 20/100 in the eye to be implanted.

          4. Subjects must have distance visual acuity correctable to at least 20/20 in both eyes.

          5. Subjects must have a preoperative spherical equivalent of plano defined as Plano to
             -0.75D with no more than 0.75D of refractive cylinder as determined by cycloplegic
             refraction in the eye to be implanted.

          6. Subjects must have a stable refraction twelve months prior to ACI implantation: i.e.
             MRSE within 0.50D over prior twelve months as determined by subject history.

          7. Subjects who are soft contact lens wearers must discontinue their contact lenses for
             at least one week prior to ACI pre-operative examination.

          8. Subjects must have a minimum central corneal thickness of = 500 microns in the eye to
             be implanted.

          9. Subjects must have a corneal power of = 41.00D and = 47.00D in all meridians in the
             eye to be implanted.

         10. Subjects must be = 45 years and = 60 years of age at the time of subject eligibility
             visit.

         11. Subjects must have an endothelial cell count = 2000 cells/mm2 in the eye to be
             implanted.

         12. Subjects must be willing and able to return for scheduled follow-up examinations for
             12 months after surgery.

         13. Subjects must demonstrate tolerance to monovision blur in the eye to be implanted as
             determined by loose lens blur tolerance or monovision contact lens trial.</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Subjects with a difference of &gt;1.00D between the spherical equivalent manifest
             refraction and the spherical equivalent cycloplegic refraction.

          2. Subjects with anterior segment pathology, including cataracts, in the eye to be
             implanted.

          3. Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or
             any corneal abnormality (including endothelial dystrophy, guttata, recurrent corneal
             erosion, etc.) in the eye to be implanted.

          4. Subjects with ophthalmoscopic or topographic signs of keratoconus (or keratoconus
             suspect) or keratoectasia in the eye to be implanted.

          5. Subjects with dry eye as determined by objective testing; anesthetized Schirmer's test
             result &lt;10 mm or a tear break-up time (TBUT) less than 10 seconds are excluded.

          6. Subjects taking chronic systemic medications known to exacerbate or induce moderate to
             severe dry eye in so far as measures of TBUT and Schirmers are decreased or borderline
             per Exclusion Criterion #5. Subjects taking the following classes of medications
             should be evaluated: anti-depressants, anti-histamines, beta-blockers, phenothiazines,
             atropine and atropine derivatives, oral contraceptives, anxiolytics, diuretics,
             anti-cholinergics, and anti-arrhythmics.

          7. Subjects with distorted or unclear corneal mires on topography maps of the eye to be
             implanted.

          8. Subjects with macular degeneration, retinal detachment, or any other fundus pathology
             that would prevent an acceptable visual outcome in the eye to be implanted.

          9. Subjects who have worn RGP or PMMA contact lenses within the last 6 months.

         10. Subjects who have undergone previous intraocular or corneal surgery, including PRK,
             LASIK, CK, LASEK, and cataract surgery in the eye to be implanted.

         11. Subjects with a history of herpes zoster or herpes simplex keratitis.

         12. Subjects who have a history of steroid-responsive rise in intraocular pressure,
             preoperative IOP &gt; 21 mmHg, glaucoma, ocular hypertension, or are glaucoma suspects.

         13. Subjects with an abnormal threshold visual field.

         14. Subjects with a history of diagnosed diabetes, diagnosed autoimmune disease,
             connective tissue disease, or clinically significant atopic syndrome.

         15. Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that
             may affect wound healing, and any immunocompromised subjects.

         16. Subjects who are using ophthalmic medication(s) other than artificial tears for
             treatment of any ocular pathology including ocular allergy.

         17. Subjects using systemic medications with significant ocular side effects.

         18. Subjects who are pregnant, lactating, or of child-bearing potential and not practicing
             a medically approved method of birth control.

         19. Subjects with known sensitivity to planned study concomitant medications.

         20. Subjects who are participating in any other ophthalmic drug or device clinical trial
             during the time of this clinical investigation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>151</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Vision Eye Institute - Bondi Junction</hospital>
    <postcode>2022 - Bondi Junction</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Makati City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AcuFocus, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will
      provide an effective method of for the correction of presbyopia in patients who have normal
      distance vision but need correction such as glasses or contact lenses to see clearly at near.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01352442</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Perry Binder, MD</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>